Moloney Securities Asset Management LLC Buys 54,332 Shares of Pfizer Inc. (NYSE:PFE)

Moloney Securities Asset Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 314.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,600 shares of the biopharmaceutical company's stock after acquiring an additional 54,332 shares during the quarter. Moloney Securities Asset Management LLC's holdings in Pfizer were worth $1,814,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $30,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Leerink Partners cut their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Bank of America lifted their price target on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.55.

Pfizer Price Performance

Pfizer stock traded up $0.21 on Thursday, reaching $25.77. The company's stock had a trading volume of 39,477,537 shares, compared to its average volume of 41,842,555. The company has a market cap of $146.49 billion, a price-to-earnings ratio of 18.67, a PEG ratio of 0.93 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The business's fifty day moving average price is $23.86 and its 200 day moving average price is $24.81.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.82 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.68%. Pfizer's payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.